- Posts: 1359
- Thank you received: 36
ramage wrote: I read this study earlier and have some comments.
1. This is a retrospective case analysis, gleaned from the medical records after the fact. 2. There is discussion as to the actual drug regimen of each patient. 3. There was no determination as to whether Zinc was also given to the patients. 4. As Dr Brix stated, today, the important thing to take away from this article is the linkage of co-morbidity and the virus
5. I found it interesting that the study included patients "We included all patients hospitalised between Dec 20, 2019, and April 14, 2020, at hospitals participating in the registry and with PCR-confirmed COVID-19 infection, for whom a clinical outcome of either hospital discharge or death during hospitalisation was recorded." The inference is that HCQ and AZ was given in December of 2019.
ramage wrote: From your Lancet citation:
"We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. "
A registry analysis is one in which the records are looked at after the fact, i.e. treatment has been given. That is what retrospective means, not that some of the records were from, last week, last month, or last year.
The defining element in this particular analysis is that of comparing outcomes after the therapy has been ended. There is no control over what, how much or when the drugs were given.
I hope that this clears up any confusion.